hero image

BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

April 9, 2024 News Release

Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open.

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. An archived version of the webcast will be available for at least 90 days following the presentation.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.


We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - FacebookLinkedIn, X, YouTube.

 

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human

thumb
April 24, 2024
Biogen Reports First Quarter 2024 Results